Moomoo AI 已提取核心訊息
On February 15, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the Nasdaq Stock Market's listing standards regarding bid price and publicly held shares. The company received a letter from Nasdaq on February 13, 2024, confirming that it has met the minimum bid price and publicly held shares requirements, as per Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). Panbela also plans to present its equity compliance plan to the Nasdaq Hearings Panel. The company's pipeline includes clinical trials focusing on various cancers, with its lead assets being Ivospemin (SBP-101) and Flynpovi. Panbela's stock is traded on the Nasdaq under the symbol 'PBLA'. The announcement also included cautionary statements regarding forward-looking statements, outlining potential risks and uncertainties that could affect the company's future results and financial condition.
On February 15, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it has regained compliance with the Nasdaq Stock Market's listing standards regarding bid price and publicly held shares. The company received a letter from Nasdaq on February 13, 2024, confirming that it has met the minimum bid price and publicly held shares requirements, as per Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). Panbela also plans to present its equity compliance plan to the Nasdaq Hearings Panel. The company's pipeline includes clinical trials focusing on various cancers, with its lead assets being Ivospemin (SBP-101) and Flynpovi. Panbela's stock is traded on the Nasdaq under the symbol 'PBLA'. The announcement also included cautionary statements regarding forward-looking statements, outlining potential risks and uncertainties that could affect the company's future results and financial condition.
2024年2月15日，處於臨床階段的生物製藥公司Panbela Therapeutics, Inc. 宣佈，它已恢復遵守納斯達克股票市場關於出價和公開持股的上市標準。該公司於2024年2月13日收到納斯達克的一封信，確認其已達到《納斯達克上市規則》第5550（a）（2）和5550（a）（4）條的最低出價和公開持股要求。Panbela還計劃向納斯達克聽證會小組提交其股票合規計劃。該公司的產品線包括以各種癌症爲重點的臨床試驗，其主要資產是Ivospemin（SBP-101）和Flynpovi。Panbela的股票在納斯達克上市，股票代碼爲 “PBLA”。該公告還包括有關前瞻性陳述的警示性陳述，概述了可能影響公司未來業績和財務狀況的潛在風險和不確定性。
2024年2月15日，處於臨床階段的生物製藥公司Panbela Therapeutics, Inc. 宣佈，它已恢復遵守納斯達克股票市場關於出價和公開持股的上市標準。該公司於2024年2月13日收到納斯達克的一封信，確認其已達到《納斯達克上市規則》第5550（a）（2）和5550（a）（4）條的最低出價和公開持股要求。Panbela還計劃向納斯達克聽證會小組提交其股票合規計劃。該公司的產品線包括以各種癌症爲重點的臨床試驗，其主要資產是Ivospemin（SBP-101）和Flynpovi。Panbela的股票在納斯達克上市，股票代碼爲 “PBLA”。該公告還包括有關前瞻性陳述的警示性陳述，概述了可能影響公司未來業績和財務狀況的潛在風險和不確定性。
有用
沒用
